Giovanna Pinto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Giovanna Pinto has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Adrián Vizoso
Perioperative Medicine Research Group, Hospital del Mar Research Institute, 08003 Barcelona, Spain
1 shared publication - Berta Fabregó
Department of Obstetrics and Gynecology, Hospital del Mar, 08003 Barcelona, Spain
1 shared publication - Ester Miralpeix
Department of Obstetrics and Gynecology, Gynecological Cancer Multidisciplinary Unit, Hospital del Mar Research Institute, Barcelona, Spain; Pompeu Fabra University, Faculty of Medicine and Life Science, Barcelona, Spain
1 shared publication - Gemma Mancebo
Department of Obstetrics and Gynecology, Hospital del Mar, 08003 Barcelona, Spain
1 shared publication - Josep Maria Solé Sedeño
Department of Obstetrics and Gynecology, Hospital del Mar, 08003 Barcelona, Spain
1 shared publication - Marta Alvarez
Department of Obstetrics and Gynecology, Hospital del Mar, 08003 Barcelona, Spain
1 shared publication
Latest Publications
- Open Access
Influence of Age on Treatment and Prognosis in Ovarian Cancer Patients
Background: Ovarian cancer, particularly in advanced stages, requires cytoreductive surgery followed by chemotherapy. A significant proportion of patients are elderly, yet older women are often treated with non-standard regimens despite a lack of consistent evidence linking age to prognosis. The aim of this study is to assess age-specific differences in treatment and survival outcomes for ovarian cancer in women aged 70 years or older. Methods: This retrospective study included ovarian cancer patients treated at the Hospital del Mar, Barcelona, between 2016 and 2022. Patients were stratified into two groups: p = 0.012). Patients aged ≥70 were more likely to undergo interval surgery (p = 0.053) and receive non-standard treatment (p = 0.023). Complete cytoreduction was achieved in 95.8% of younger patients versus 81.3% of older patients (p = 0.024). Age ≥70 did not significantly impact DFS (p = 0.091), but OS was significantly worse in the older group (44.4% vs. 67.2%, p = 0.014). Conclusions: Older women (≥70 years) with ovarian cancer are more likely to be diagnosed at advanced stages, receive non-standard treatment, and achieve suboptimal cytoreduction compared to younger patients. While DFS was similar across age groups, older age was associated with worse OS, highlighting the need for age-tailored treatment strategies.
Open AccessInfluence of Age on Treatment and Prognosis in Ovarian Cancer Patients
Background: Ovarian cancer, particularly in advanced stages, requires cytoreductive surgery followed by chemotherapy. A significant proportion of patients are elderly, yet older women are often treated with non-standard regimens despite a lack of consistent evidence linking age to prognosis. The aim of this study is to assess age-specific differences in treatment and survival outcomes for ovarian cancer in women aged 70 years or older. Methods: This retrospective study included ovarian cancer patients treated at the Hospital del Mar, Barcelona, between 2016 and 2022. Patients were stratified into two groups: p = 0.012). Patients aged ≥70 were more likely to undergo interval surgery (p = 0.053) and receive non-standard treatment (p = 0.023). Complete cytoreduction was achieved in 95.8% of younger patients versus 81.3% of older patients (p = 0.024). Age ≥70 did not significantly impact DFS (p = 0.091), but OS was significantly worse in the older group (44.4% vs. 67.2%, p = 0.014). Conclusions: Older women (≥70 years) with ovarian cancer are more likely to be diagnosed at advanced stages, receive non-standard treatment, and achieve suboptimal cytoreduction compared to younger patients. While DFS was similar across age groups, older age was associated with worse OS, highlighting the need for age-tailored treatment strategies.